BeaconEquity.com announces the publication of an article covering Genta's phase 3 trial success of Genasense®.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“Genta Inc. (OTCBB: GNTA) is a bio-pharmaceutical company focused on the treatment of various cancers. The company recently announced it has passed phase 3 trial analyses of Genasense ® for the treatment of advanced melanoma.”
An independent board recommends Genta's study should continue through completion:
“According to an independent Data Monitoring Board (DMB) for AGENDA, Genesense passed the futility and safety tests and is now ready for further trials and recommends the study should continue through completion.”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
